EGFR and non-small cell lung carcinoma: Although afatinib was approved as a first-line chemotherapeutic drug for patients with NSCLC harboring the EGFR-activating mutation, the clinical dose of this drug cannot reach a concentration that will inhibit T790M mutant EGFR [93,94].